These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 33944938)

  • 1. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
    Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
    Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
    Haller H
    Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiorenal benefits of finerenone: protecting kidney and heart.
    González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
    Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
    Barrera-Chimal J; Lima-Posada I; Bakris GL; Jaisser F
    Nat Rev Nephrol; 2022 Jan; 18(1):56-70. PubMed ID: 34675379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
    Kim DL; Lee SE; Kim NH
    Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
    Yao L; Liang X; Wang P
    Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
    DeFronzo RA; Bakris GL
    Diabetes Obes Metab; 2022 Jul; 24(7):1197-1205. PubMed ID: 35302284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS;
    JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
    Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
    Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
    Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A
    Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
    Raj R
    Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.